Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The medicine is now approved for eight indications across five different types of cancer in China.
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
